Related Experiment Video
Updated: Jun 2, 2026
14:24
Percutaneous Contrast Echocardiography-guided Intramyocardial Injection and Cell Delivery in a Large Preclinical Model
Published on: January 21, 2018
Cachexia in heart disease: highlights from the ESC 2010
Journal of Cachexia, Sarcopenia and Muscle
|April 9, 2011
Summary
Cardiac cachexia, affecting up to 15% of heart failure patients, involves muscle wasting. Exercise training and understanding protein degradation pathways, like the ubiquitin-proteasome system, show promise for new treatments.
Area of Science:
- Cardiology
- Muscle Metabolism
- Heart Failure Research
Background:
- Cardiac cachexia is a common comorbidity in advanced chronic heart failure (CHF), affecting up to 15% of patients.
- Muscle metabolism alterations in heart disease are gaining research attention.
- Recent studies presented at the European Society of Cardiology meeting focused on cardiac cachexia.
Purpose of the Study:
- To highlight recent research on cardiac cachexia, focusing on exercise training and protein degradation.
- To explore the role of the ubiquitin-proteasome complex and specific ubiquitin ligases (MuRF-1, MAFbx).
- To investigate the relationship between adiponectin, myostatin, follistatin, and muscle wasting in heart failure.
Main Methods:
- Review of studies presented at the European Society of Cardiology meeting (September 2010).
- Analysis of exercise training effects on maximal oxygen consumption and MuRF-1 expression in CHF patients.
- Examination of inflammatory cytokines' role in muscle protein degradation.
- Measurement of serum adiponectin levels and their correlation with body composition.
- Assessment of myostatin and follistatin expression in skeletal muscle of rats with heart failure.
Main Results:
- Exercise training in CHF patients improved maximal oxygen consumption and reduced MuRF-1 expression.
- Lysosomal degradation plays a minor role; inflammatory cytokines like TNF-α drive muscle protein breakdown.
- Elevated serum adiponectin levels in CHF patients correlate with muscle mass and strength.
- Myostatin and follistatin expression decreased in the skeletal muscle of rats with heart failure, suggesting a role in muscle wasting.
Conclusions:
- Exercise training offers benefits for patients with chronic heart failure and cardiac cachexia.
- The ubiquitin-proteasome pathway is a key player in cardiac cachexia-related muscle protein degradation.
- Adiponectin, myostatin, and follistatin may serve as biomarkers and therapeutic targets for muscle wasting in heart failure.
Related Concept Videos
01:29Heart Failure II: Pathophysiology
Systolic Heart Failure and Compensatory MechanismsSystolic heart failure (also termed HFrEF, Heart Failure with Reduced Ejection Fraction) is the most prevalent type of heart filure. It results in a decreased volume of blood being pumped from the ventricle. The aortic arch and carotid sinuses have baroreceptors that detect reduced blood pressure, triggering the sympathetic nervous system (SNS) to release epinephrine and norepinephrine. Initially, this response aims to boost heart rate and...
01:26Heart Failure III: Clinical Manifestations
Heart failure (HF) manifests primarily as dyspnea, fatigue, and fluid retention, resulting in peripheral and pulmonary edema. Symptoms may vary depending on which ventricle is more affected, left or right.Left-Sided Heart FailureAlso known as left ventricular failure, this condition results from the left ventricle's inability to fill or eject sufficient blood into the systemic circulation. It leads to pulmonary congestion, which occurs when the left ventricle fails to eject blood effectively...
01:27Heart Failure I: Introduction
Heart failure refers to a clinical syndrome caused by structural or functional cardiac disorders that prevent the heart from pumping an adequate amount of blood to meet the body's metabolic needs. This condition often arises from myocardial infarction or ischemia, leading to decreased cardiac output, reduced tissue perfusion, impaired gas exchange, fluid volume imbalance, and decreased functional ability.Heart failure can result from disruptions in the mechanisms that regulate cardiac output...
01:17Pathophysiology of Heart Failure
Heart failure (HF) is a progressive syndrome involving ventricles that leads to inadequate cardiac output. It can be classified based on location and output or ejection fraction. Ejection fraction (EF) is an essential measurement in the diagnosis and surveillance of HF. Reduced EF corresponds to systolic heart failure (HFrEF). However, HF with preserved ejection fraction (HFpEF) is becoming increasingly prevalent. Also known as diastolic HF, this form of HF is related to aging. The...
01:17Ischemic Heart Disease: Overview
Ischemic heart disease occurs when the heart's blood supply dwindles, causing an ominous lack of oxygen and nutrients. This deficiency, stemming from reduced or obstructed blood flow, spells danger, leading to heart muscle damage and dysfunction.
Atherosclerosis, the primary malefactor, orchestrates this dangerous condition. It manifests as the accumulation of fatty deposits, akin to insidious plaques, within arterial walls. As time elapses, these plaques metamorphose, hardening and narrowing...
Atherosclerosis, the primary malefactor, orchestrates this dangerous condition. It manifests as the accumulation of fatty deposits, akin to insidious plaques, within arterial walls. As time elapses, these plaques metamorphose, hardening and narrowing...
01:29Cardiomyopathy III: Hypertrophic Cardiomyopathy
Hypertrophic cardiomyopathy, or HCM, is an autosomal dominant genetic disorder characterized by asymmetric left ventricular hypertrophy without ventricular dilation. It is more common in men and is typically diagnosed in young, athletic adults.EtiologyHCM is primarily genetic and is caused by mutations in genes encoding sarcomeric proteins. Researchers have identified over 1400 mutations across at least 11 different genes. Among these, the most frequently occurring mutations are found in the...